logo-cropped

Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting

Tuesday, 12 November 2013 07:30
(function(){ var wrap = document.getElementById("yom-ad-LREC"); if (null == wrap) { wrap = document.getElementById("yom-ad-LREC-iframe") || {}; } var content = wrap.innerHTML || ""; if (content && content.substr(0, content.lastIndexOf(" BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. (“Senesco” or the “Company”) (SNTID) announced today that it will make two presentations on its gene regulation technology (SNS01-T) for blood-borne cancer care at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 7-10th in…
Geron Corporation Reports Third Quarter 2013 Financial Results
Sunday, 10 November 2013 08:15
Conference Call Scheduled for 4:30 p.m. EST Today, November 7th MENLO PARK, Calif., November 7, 2013 -- Geron Corporation (GERN) today reported financial results for the third quarter ended September 30, 2013. For the third quarter of 2013, the company reported a net loss of $8.3 million, or $0.06 per share, compared to $16.0 million, or $0.13 per share, for the comparable 2012 period. Net loss for the first nine months of 2013 was $29.1…
4 New Orleans Startups Compete For Cash
Friday, 08 November 2013 11:45
NEW ORLEANS (AP) -- Four New Orleans biotech startup companies will compete for an infusion of cash in front of a panel of industry experts and investors later this month. The New Orleans BioInnovation Center, a nonprofit technology business incubator, is holding the competition as part of a larger entrepreneur conference called Innovation Louisiana 2013 on Nov. 18-20. The Times-Picayune reports (http://bit.ly/1iRJLvE) that the competitors' have interests ranging from forensic DNA testing to treatment of…
Genmab to Present Product and Proprietary Technology data at American Society of Hematology Annual Meeting (ASH)
Thursday, 07 November 2013 08:46
Company AnnouncementSix Genmab abstracts accepted for presentation at ASHFirst preliminary data from Phase I/II daratumumab combination study in multiple myeloma Data from Phase III study of ofatumumab (COMPLEMENT 1) Copenhagen, Denmark; November 7, 2013 - Genmab A/S (GEN.CO) announced today that six Genmab abstracts which include data on daratumumab, ofatumumab and the novel HexaBody(tm) technology have been accepted for presentation at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition December 7-11 in…
MissionIR Releases Exclusive Audio Interview With CytRx Management
Thursday, 07 November 2013 07:45
ATLANTA, GA--(Marketwired - Nov 7, 2013) - MissionIR today announces the online availability of its interview with CytRx Corp. (NASDAQ: CYTR) President and Chief Executive Officer Steven Kriegsman, as well as the company's Vice President of Business Development and Investor Relations David Haen. The full audio interview is available at: http://cytr.missionir.com/interview.html. CytRx is a biopharmaceutical R&D company developing cancer drugs for several indications. The company's primary focus is on its proprietary delivery technology for potent…
InPlay from Briefing.com
Wednesday, 06 November 2013 09:15
10:12 am Relative sector weakness (:TECHX) : Sectors that are underperforming include: Biotech IBB, Health XLV, Semi SMH, Bank KBE, Retail XRT, Transports IYT, Oil Service OIH, Energy XLE. 10:03 am Dow +105 and S&P +9.7 hover just under highs, Nasdaq Comp +11 and small caps firmer but lagging (:TECHX) : 10:03 am Honeywell announces Midea, a Chinese appliance manufacturer, will adopt co's next-generation Solstice Liquid Blowing Agent to insulate Midea refrigerators and freezers (HON)…
BEIGE BOOK: Uncertainty Increased Due To The Budget Deadlock
Friday, 18 October 2013 08:00
Wikimedia Commons The Federal Reserve's Beige Book is out, featuring anecdotes collected by the Fed's regional banks. " Contacts across Districts generally remained cautiously optimistic in their outlook for future economic activity, although many also noted an increase in uncertainty due largely to the federal government shutdown and debt ceiling debate," according to the report. The Boston Fed reported, " Firms doing business with the government have been affected by the sequester; other firms are…
MARKET PULSE- Citigroup, Savient Pharmaceuticals, Teradata, J&J, Fedex
Tuesday, 15 October 2013 09:00
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Wall Street was set for a flat open on Tuesday after afour-session rally on the S&P 500 as investors focused ondevelopments in the budget talks and a batch of corporateearnings including Citigroup (NYSE: C - news) . S&P 500 futures lost 0.8 points and were in line withfair value, a formula that…
MARKET PULSE- Citigroup, Savient Pharmaceuticals, Teradata, J&J, Coca-Cola
Tuesday, 15 October 2013 08:00
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock futures edged lower on Tuesday after Citigroup (NYSE: C - news)reported a marginal fall in adjusted quarterly profit fromongoing businesses. S&P 500 futures lost 1.5 points and were slightlybelow fair value, a formula that evaluates pricing by takinginto account interest rates, dividends and time to expiration onthe contract. Dow Jones…
MARKET PULSE- Savient Pharmaceuticals, Teradata, Microsoft, Omnicom
Tuesday, 15 October 2013 08:00
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) ** SAVIENT PHARMACEUTICALS INC (NasdaqGM: SVNT - news) , Monday close $0.57,down 30 pct premarket The U.S. biotech firm filed for Chapter 11 bankruptcyprotection in a Delaware court on Monday and said it has agreedto sell most of its assets to Sloan Holdings CV for about $55million. The agreement with Sloan, a…
Create your free online surveys with SurveyMonkey , the world's leading questionnaire tool.

latter-blum2

Share Bayoubuzz

Powered By JFBConnect